MCF7/LCC2: A 4-Hydroxytamoxifeii Resistant Human Breast Cancer Variant That Retains Sensitivity to the Steroidal Antiestrogen ICI 182,780

Nils Briinner, Thomas L. Frandsen, Claus Holst-Hansen, Mian Bei, Erik W. Thompson, Alan E. Wakeling, Marc E. Lippman, Robert Clarke

Research output: Contribution to journalArticle

190 Scopus citations

Abstract

The development of resistance to the antiestrogen tamoxifen occurs in a high percentage of initially responsive patients. We have developed a new model in which to investigate acquired resistance to triphenylethylenes. A stepwise in vitro selection of the hormone-independent human breast cancer variant MCF-7/LCC1 against 4-hydroxytamoxifen produced a stable resistant population designated MCF7/LCC2. MCF7/LCC2 cells retain levels of estrogen receptor expression comparable to the parental MCF7/LCC1 and MCF-7 cells. Progesterone receptor expression remains estrogen inducible in MCF7/LCC2 cells, although to levels significantly lower than observed in MCF-7 and MCF7/LCC1 cells. MCF7/ LCC2 cells form tumors in ovariectomized nude mice without estrogen supplementation, and these tumors are tamoxifen resistant but can be tstrogen stimulated. Significantly, MCF7/LCC2 cells have retained sensitivity to the steroidal antiestrogen ICI 182,780. These data suggest that some breast cancer patients who acquire resistance to tamoxifen may not develop cross-resistance to treatment with steroidal antiestrogens.

Original languageEnglish (US)
Pages (from-to)3229-3232
Number of pages4
JournalCancer Research
Volume53
Issue number14
StatePublished - Aug 1993

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'MCF7/LCC2: A 4-Hydroxytamoxifeii Resistant Human Breast Cancer Variant That Retains Sensitivity to the Steroidal Antiestrogen ICI 182,780'. Together they form a unique fingerprint.

  • Cite this

    Briinner, N., Frandsen, T. L., Holst-Hansen, C., Bei, M., Thompson, E. W., Wakeling, A. E., Lippman, M. E., & Clarke, R. (1993). MCF7/LCC2: A 4-Hydroxytamoxifeii Resistant Human Breast Cancer Variant That Retains Sensitivity to the Steroidal Antiestrogen ICI 182,780. Cancer Research, 53(14), 3229-3232.